Advinus Therapeutics and P2D Bioscience Enter Into a Research and Development Collaboration for Attention Deficit Hyperactivity Disorder (ADHD)

Advinus Therapeutics Ltd., a drug discovery and development company, and P2D Bioscience, a CNS-focused specialty pharmaceutical company, have initiated a research and development collaboration to develop therapies for Attention Deficit Hyperactivity Disorder (ADHD). Visit P2Dinc.com to learn more. Tweet

P2D Bioscience Receives NIH Funding to Develop Drugs for Lung Disease

P2D Bioscience has received a $320,000 grant from the U.S. National Heart, Lung and Blood Institute. The purpose of this grant is to develop a novel class of anti-inflammatory drugs specifically targeting lung diseases, including acute lung injury/acute respiratory distress syndrome, chronic obstructive pulmonary disease (COPD) and asthma. Click here to read the entire release. […]